Armata Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Armata Pharmaceuticals's earnings have been declining at an average annual rate of -28.8%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 35.8% per year.
Key information
-28.8%
Earnings growth rate
6.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 35.8% |
| Return on equity | n/a |
| Net Margin | -756.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Armata Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5 | -41 | 13 | 0 |
| 30 Jun 24 | 4 | -67 | 13 | 0 |
| 31 Mar 24 | 5 | -80 | 12 | 0 |
| 31 Dec 23 | 5 | -69 | 12 | 0 |
| 30 Sep 23 | 4 | -60 | 10 | 0 |
| 30 Jun 23 | 4 | -37 | 8 | 0 |
| 31 Mar 23 | 5 | -43 | 8 | 0 |
| 31 Dec 22 | 6 | -37 | 7 | 0 |
| 30 Sep 22 | 5 | -33 | 8 | 0 |
| 30 Jun 22 | 5 | -29 | 8 | 0 |
| 31 Mar 22 | 5 | -26 | 8 | 0 |
| 31 Dec 21 | 4 | -23 | 8 | 0 |
| 30 Sep 21 | 4 | -24 | 8 | 0 |
| 30 Jun 21 | 3 | -24 | 8 | 0 |
| 31 Mar 21 | 2 | -23 | 8 | 0 |
| 31 Dec 20 | 1 | -22 | 8 | 0 |
| 30 Sep 20 | 0 | -20 | 10 | 0 |
| 30 Jun 20 | 0 | -21 | 11 | 0 |
| 31 Mar 20 | 0 | -21 | 11 | -2 |
| 31 Dec 19 | 0 | -19 | 10 | 0 |
| 30 Sep 19 | 0 | -16 | 8 | 1 |
| 30 Jun 19 | 0 | -12 | 5 | 2 |
| 31 Mar 19 | 0 | -11 | 4 | 7 |
| 31 Dec 18 | 0 | -17 | 4 | 7 |
Quality Earnings: ARMP is currently unprofitable.
Growing Profit Margin: ARMP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARMP is unprofitable, and losses have increased over the past 5 years at a rate of 28.8% per year.
Accelerating Growth: Unable to compare ARMP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARMP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ARMP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.